Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner

Fig. 1

Downregulation of the m6A demethylase ALKBH5 characterizes pancreatic cancer (PC). a The ALKBH5 mRNA level demonstrated significantly decreased in PC tissues. b Immunohistochemistry staining showed masses of ALKBH5-positively stained cells in normal control tissues and well-differentiated PC tissues, while negative staining in poorly differentiated PC tissues. c Western blotting verified the decreased ALKBH5 level in poorly differentiated PC samples (T) when compared to noncancerous controls (N). d The elevation of mRNA m6A levels in PC samples depended on the loss of ALKBH5. e, f PC patients from the Kaplan-Meier Plotter dataset e and 42 matched PC specimens f displayed a significant correlation between low ALKBH5 expression (median split) and shorter OS times. A Kaplan-Meier survival curve with log-rank test was applied for prognostic evaluation. Bar graph indicates the means ± SDs of 3 independent experiments. β-actin and GAPDH are used as internal controls in western blotting and qRT-PCR assays, respectively. *P < 0.05, **P < 0.01, and ***P < 0.001

Back to article page

Molecular Cancer

ISSN: 1476-4598